Since the first spin-off created in 1997, many companies have started their activity at the Institut Pasteur and remain globally in relation with the Institute.
Eligo Bioscience is a next-generation microbiome precision medicine company. Eligo Bioscience is pioneering the development of phage-derived DNA delivery vectors for microbial species involved in a number of disease areas, including infectious diseases, inflammatory diseases and auto-immune diseases.
Eligo Bioscience was created in 2014 based on research from the Lu Lab (MIT, USA) and the Marraffini Lab (Rockefeller University, USA). Eligo was incubated at the Institut Pasteur in Paris from 2014 to 2017 and moved in 2017 into the biotech cluster “Paris Biotech Santé” at the Cochin Hospital.
David Bikard, Cofounder and CSO at Eligo Bioscience, is the head of the synthetic biology lab at the Institut Pasteur.
David Bikard, Cofounder and CSO at Eligo Bioscience, is the head of the synthetic biology lab at the Institut Pasteur
Xavier Duportet, Cofounder and CEO at Eligo Bioscience
Our continued collaboration with the Institut Pasteur creates a continuous link between basic research and real life applications while providing access to important biological resources and cutting edge technologies. This fluid interaction is critical to our progress.